Please login to the form below

Not currently logged in
Email:
Password:

First new COPD inhaler in 8 years launches

Novartis has launched the Onbrez Breezhaler (indacaterol), a once-daily LABA for use in Chronic Obstructive Pulmonary Disease (COPD), in the UK

The Onbrez Breezhaler (indacaterol), a new 24-hour once-a-day drug for use in Chronic Obstructive Pulmonary Disease (COPD), has been launched in the UK by Novartis. The long-acting beta agonist (LABA) is the first new COPD treatment to be introduced to the UK for eight years and is the first 24-hour once-daily COPD treatment to be available.

The European Medicines Agency (EMA) granted indacaterol an EU-wide licence in November 2009, based on the results of clinical trials in over 2,000 patients. These trials showed that indacaterol provided bronchodilation within five minutes and this effect lasted for 24 hours. This resulted in a clinically significant improvement in breathlessness at six months versus placebo.

Dr Steve Holmes, chair of the Primary Care Respiratory Society and a member of the British Thoracic Society Education Committee, commented: "This new treatment is great news as it offers a once daily treatment for people with COPD suffering from breathlessness. The early research shows significant improvements in patients' quality of life."

Indacaterol is a COPD maintenance therapy and is not for use either as a reliever or to treat asthma.

11th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...
New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....

Infographics